Core Points - On September 29, 2025, the company announced that its controlling shareholder, Yabao Investment, received a notice of pledge release [1] - Yabao Investment repurchased 13,650,000 unrestricted circulating shares that were pledged to Shanxi Securities Co., Ltd. through a stock pledge repurchase transaction [1] - Following the completion of the repurchase transaction, the corresponding shares' pledge was released [1]

| 股东名称 | 亚宝投资 | | --- | --- | | 本次解除质押股份 | 13,650,000 股 | | 占其所持股份比例 | 14.48% | | 占公司总股本比例 | 1.95% | | 解除质押时间 | 2025 年 9 月 26 日 | | 持股数量 | 94,300,000 股 | | 持股比例 | 13.47% | | 剩余被质押股份数量 | 24,950,000 股 | | 剩余被质押股份数量占其所持股份比例 | 26.46% | | 剩余被质押股份数量占公司总股本比例 | 3.56% | 证券代码：600351 证券简称：亚宝药业 公告编号：2025-036 亚宝药业集团股份有限公司 关于控股股东股票质押式回购交易股份提前购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告披露日，亚宝药业集团股份有限公司（以下简称"公司"）控 股股东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有本公司股份 94,300,000股，占公司总股本的13.47%；本次质押解除后 ...

Core Viewpoint - Yabao Pharmaceutical announced that its controlling shareholder, Yabao Investment, completed the early repurchase of 13,650,000 shares of unrestricted circulating stock through a pledged repurchase transaction on September 26, leading to the release of the corresponding pledge [1] Summary by Relevant Sections - Shareholding Structure - As of the announcement date, Yabao Investment holds 94,300,000 shares, accounting for 13.47% of the total share capital [1] - After the release of the pledge, the total pledged shares amount to 24,950,000, which represents 26.46% of Yabao Investment's total holdings and 3.56% of the company's total share capital [1] - Pledged Shares - Yabao Investment and its concerted parties collectively hold 97,300,000 shares, which is 13.90% of the total shares, with a cumulative pledge of 24,950,000 shares [1] - Company Monitoring - The company will closely monitor the pledge matters and disclose information in a timely manner [1]

■ 2、本次被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或用于其他保障用途。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告日，亚宝药业集团股份有限公司（以下简称"公司"）控股股东山西亚宝投资集团有限公司 （以下简称"亚宝投资"）持有本公司股份94,300,000股，占公司总股本的13.47%；亚宝投资所持有的公 司股份累计质押股份数为38,600,000股，占其持有公司股份总数的40.93%，占公司总股本的5.51%。 公司于2025年9月26日接到控股股东亚宝投资关于进行股票质押式回购交易的通知，现将相关情况公告 如下： 一、本次股份质押的情况 1、本次质押式回购交易涉及的股份质押情况 二、股东累计质押股份的情况 截至公告披露日，亚宝投资及其一致行动人累计质押股份情况如下： ■ 公司将密切关注亚宝投资股份质押事项并按照相关法律法规要求及时履行信息披露义务。 特此公告。 亚宝药业集团股份有限公司董事会 2025年9月27日 ...

Group 1 - The core point of the article is that Yabao Pharmaceutical has significant shareholding and pledge details from its controlling shareholder, along with its revenue composition for the upcoming year [1] Group 2 - As of the announcement date, Yabao Pharmaceutical's controlling shareholder, Shanxi Yabao Investment Group, holds 94.3 million shares, accounting for 13.47% of the total share capital [1] - The total number of pledged shares by Yabao Investment is 38.6 million, which represents 40.93% of its holdings and 5.51% of the company's total share capital [1] - For the year 2024, Yabao Pharmaceutical's revenue composition is projected to be 75.46% from pharmaceutical manufacturing, 21.37% from pharmaceutical wholesale, 1.88% from other trading, and 1.29% from other businesses [1] - The current market capitalization of Yabao Pharmaceutical is 4.6 billion yuan [1]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-035 亚宝药业集团股份有限公司 公司于2025年9月26日接到控股股东亚宝投资关于进行股票质押式回购交易 的通知，现将相关情况公告如下： 二、股东累计质押股份的情况 关于控股股东进行股票质押式回购交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告日，亚宝药业集团股份有限公司（以下简称"公司"）控股股 东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有本公司股份 94,300,000股，占公司总股本的13.47%；亚宝投资所持有的公司股份累计质押股 份数为38,600,000股，占其持有公司股份总数的40.93%，占公司总股本的5.51%。 一、本次股份质押的情况 | 股东 | 是否为 | 本次质押股 | 是否为限售 | 是否 | 质押起 | 质押到 | | 占其所 | 占公司 | 质押 融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...

亚宝药业公告称，26日接到控股股东亚宝投资股票质押式回购交易通知。9月25日，亚宝投资质押1145 万股给国泰海通证券，占其所持股份12.14%，占公司总股本1.64%，质押期限至2026年9月25日，资金 用于偿还债务。截至公告日，亚宝投资持有公司股份9430万股，占总股本13.47%，累计质押3860万 股，占其持股40.93%，占公司总股本5.51%。公司将密切关注质押事项并依规披露信息。 ...

Group 1 - The core point of the article is that Yabao Pharmaceutical has halted the clinical research of SY-009, an SGLT-1 inhibitor, due to unsatisfactory results from its Phase II clinical trial, marking the second failure in diabetes drug development for the company [1][2][3] - Yabao Pharmaceutical, originally focused on pediatric drugs, aims to transition towards innovative drugs, reducing the proportion of generic drugs from 90% to 40% and increasing investment in innovative drug development [2][3] - The decision to terminate SY-009's clinical research was based on a careful assessment of the investment risks and future market value, leading to a significant write-off of previous R&D investments totaling approximately 87.87 million yuan [3] Group 2 - The global diabetes market is projected to approach $80 billion by 2024, with China's market exceeding 70 billion yuan, indicating a vast potential for diabetes treatment [4] - The competition in diabetes treatment is intense, with ten classes of oral medications available for Type 2 diabetes, but SGLT-1 inhibitors are rarely pursued by companies [4][5] - The focus of major pharmaceutical companies has shifted towards GLP-1 class drugs due to their proven efficacy and market potential, which has led to a changing competitive landscape in diabetes medications since 2019 [6]

Core Viewpoint - A domestic pharmaceutical company, Yabao Pharmaceutical, has halted the clinical research of its oral drug SY-009, an SGLT1 inhibitor, due to unsatisfactory results from its Phase II clinical trial, marking the second failure in diabetes drug development for the company [1][2]. Group 1: Company Overview - Yabao Pharmaceutical, originally focused on pediatric drugs, is transitioning towards innovative drugs, aiming to reduce its reliance on generic drugs from 90% to 40% by 2024 [1]. - The company has invested a total of 87.87 million yuan in the development of SY-009, which will be written off as a loss due to the termination of the project [2]. Group 2: Drug Development Details - SY-009 was approved for clinical trials in July 2018 and underwent three Phase I and one Phase II clinical trials over nearly six years [2]. - The Phase II trial results indicated a lack of achievement in primary efficacy endpoints, leading to the decision to terminate further development [2][3]. Group 3: Market Context - The global diabetes treatment market is projected to reach nearly $80 billion by 2024, with China's market exceeding 70 billion yuan [3]. - The competition in diabetes treatment is intense, with various classes of oral medications available, but SGLT1 inhibitors have limited presence in the market [3][4]. - The rise of GLP-1 class drugs has shifted the competitive landscape in diabetes treatment, with significant market potential and ongoing exploration of new indications [5].

Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of ZY-A002, which is intended for the treatment of cough variant asthma in children [1][3] - ZY-A002 is classified as a traditional Chinese medicine and is in the granule form, with a registration classification of Category 1.1 [5] - The total sales amount for pediatric cough and phlegm relief traditional Chinese medicine in China is projected to be approximately 6.067 billion RMB in 2024, with public medical market sales accounting for about 4.159 billion RMB and retail pharmacy sales around 1.908 billion RMB [2] Group 2 - The clinical trial application for ZY-A002 was accepted on July 7, 2025, and it is required to conduct Phase III clinical trials before it can be produced and marketed [3] - The company has invested approximately 12.5682 million RMB in the research and development of the ZY-A002 project to date [3]